Embecta Corp (EMBC)vsWest Pharmaceutical Services Inc (WST)
EMBC
Embecta Corp
$5.29
+1.93%
HEALTHCARE · Cap: $279.90M
WST
West Pharmaceutical Services Inc
$362.31
-1.17%
HEALTHCARE · Cap: $23.93B
Smart Verdict
WallStSmart Research — data-driven comparison
West Pharmaceutical Services Inc generates 227% more annual revenue ($3.33B vs $1.02B). WST leads profitability with a 17.0% profit margin vs 8.6%. EMBC trades at a lower P/E of 3.4x. WST earns a higher WallStSmart Score of 61/100 (C+).
EMBC
Hold43
out of 100
Grade: D
WST
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-42.7%
Fair Value
$7.05
Current Price
$5.29
$1.76 premium
Margin of Safety
-45.7%
Fair Value
$168.92
Current Price
$362.31
$193.39 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Conservative balance sheet, low leverage
Strong operational efficiency at 23.7%
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Strong operational efficiency at 22.5%
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Revenue declined 8.1%
Trading at 8.5x book value
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : EMBC
The strongest argument for EMBC centers on P/E Ratio, Debt/Equity, Operating Margin.
Bull Case : WST
The strongest argument for WST centers on Altman Z-Score, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 22.5%. Revenue growth of 13.8% demonstrates continued momentum.
Bear Case : EMBC
The primary concerns for EMBC are Altman Z-Score, Market Cap, Return on Equity.
Bear Case : WST
The primary concerns for WST are Price/Book, PEG Ratio, P/E Ratio. A P/E of 43.5x leaves little room for execution misses.
Key Dynamics to Monitor
EMBC profiles as a value stock while WST is a mature play — different risk/reward profiles.
WST carries more volatility with a beta of 1.14 — expect wider price swings.
WST is growing revenue faster at 13.8% — sustainability is the question.
WST generates stronger free cash flow (81M), providing more financial flexibility.
Bottom Line
WST scores higher overall (61/100 vs 43/100), backed by strong 17.0% margins and 13.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Embecta Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Embecta Corp (EMBC) is a leading medical technology company specializing in innovative insulin delivery systems aimed at enhancing diabetes management. Born from a spin-off of Becton, Dickinson and Company, Embecta provides a comprehensive portfolio of advanced products, including cutting-edge insulin pens and syringes tailored to improve patient outcomes. With a robust focus on operational excellence and customer satisfaction, Embecta is well-positioned to capitalize on growth opportunities in the rapidly expanding diabetes care market, strengthening its leadership in this vital sector.
Visit Website →West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?